TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23161291

Group type: EXPERIMENTAL
Intervention: Endoscopy with therapeutic procedures
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors post-endoscopy
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Age >65 years, hematemesis or shock/syncope, duodenal ulcer diagnosis
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Female patients older than 65 years, comorbidities, shock/syncope presentation, time to endoscopy
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Aspirin, non-steroidal anti-inflammatory drugs, or warfarin at baseline
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Transfusions other than intravenous fluid or red blood cells within 12 hours of presentation
Number of subjects: 423
Study: 23164174

Group type: EXPERIMENTAL
Intervention: Fractionated radiosurgery (10 fractions or 5 fractions depending on life expectancy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional radiotherapy (1-10 fractions, total doses of 8-30 Gy)
Number of subjects: 60
Study: 23164314

Group type: EXPERIMENTAL
Intervention: Fish oil-based lipid emulsion (FOLE) monotherapy
Number of subjects: 57
Study: 23164485

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 1124
Study: 23164592

Group type: EXPERIMENTAL
Intervention: Elderly patients with IPAH receiving combinations of PAH drugs
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Elderly patients with IPAH
Number of subjects: 587

Group type: COMPARATOR
Intervention: Younger patients with IPAH
Number of subjects: 587
Study: 23164593

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 124

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Stents with nominal diameters ≥ 2.75 mm
Number of subjects: 124
Study: 23164721

Group type: EXPERIMENTAL
Intervention: Hypothermia (core temperature <35°C before reperfusion)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (no hypothermia)
Number of subjects: 197
Study: 23164766

Group type: EXPERIMENTAL
Intervention: Pulmonary embolism diagnosed by computed tomography
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation after pulmonary embolism diagnosis
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis detected by compression ultrasonography
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Lower-limb deep venous thrombosis
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Upper-limb deep venous thrombosis
Number of subjects: 176

Group type: COMPARATOR
Intervention: Comparison of patients with and without pulmonary embolism
Number of subjects: 176
Study: 23166141

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 0
Study: 23168248

Group type: EXPERIMENTAL
Intervention: Dynamic [18F]FDG PET scan
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dynamic [15O]H2O scan
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nonlinear regression analysis
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Image-derived input function (IDIF)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Blood sampler derived input function (BSIF)
Number of subjects: 13
Study: 23168578

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonsupplemented infants
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CHr cutoff level of 26.9 pg at 4 months
Number of subjects: 80
Study: 23168606

Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted pelvic muscle training (BFB)
Number of subjects: 183
Study: 23169500

Group type: EXPERIMENTAL
Intervention: Crizotinib therapy
Number of subjects: 1
Study: 23169503

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin 40 mg/m(2), rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2), prednisone 100 mg orally on days 1 through 5, with concomitant antiretroviral therapy
Number of subjects: 40
Study: 23169518

Group type: EXPERIMENTAL
Intervention: High-dose vincristine sulfate liposome injection (VSLI) 2.25 mg/m(2), administered once per week until response, progression, toxicity, or pursuit of HCT.
Number of subjects: 65
Study: 23169778

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 299
Study: 23170854

Group type: EXPERIMENTAL
Intervention: IV paracetamol loading dose (20 mg · kg(-1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IV paracetamol monotherapy
Number of subjects: 60
Study: 23171483

Group type: EXPERIMENTAL
Intervention: Memory Impairment Screen (MIS) with alternate versions
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Memory Impairment Screen (MIS) with the same version at first follow-up
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Overall mean scores from repeated testing
Number of subjects: 1803
Study: 23171508

Group type: EXPERIMENTAL
Intervention: Tremelimumab (1-hour infusion)
Number of subjects: 44
Study: 23171747

Group type: EXPERIMENTAL
Intervention: NOTSSdk (customized Non-Technical Skills for Surgeons rating system)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: NOTSSdk
Number of subjects: 72
Study: 23171803

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-based hydration (154 mEq/L at 3 ml Kg-1 for one hour followed by 1 ml Kg-1 for six hours) with high-dose N-acetylcysteine (NAC)
Number of subjects: 524

Group type: COMPARATOR
Intervention: 0.9% saline hydration (1 ml Kg-1 for 24 hours) with high-dose N-acetylcysteine (NAC)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate-based hydration with high-dose NAC
Number of subjects: 524

Group type: COMPARATOR
Intervention: 0.9% saline hydration with high-dose NAC
Number of subjects: 524
Study: 23172848

Group type: EXPERIMENTAL
Intervention: XIENCE V Everolimus-eluting stent
Number of subjects: 673
Study: 23172858

Group type: EXPERIMENTAL
Intervention: Waist circumference measurement at minimal waist
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Waist circumference measurement at midpoint between the iliac crest and the lowest rib
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Waist circumference measurement at superior border of the iliac crest
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Waist circumference measurement at umbilicus
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Correlation between WC and logVAT
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Correlation between WC and cardiometabolic risk factors
Number of subjects: 371
Study: 23173902

Group type: EXPERIMENTAL
Intervention: Scale for Measuring Motivational Interviewing Skills (EVEM questionnaire)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Video recorded interviews
Number of subjects: 362
Study: 23174632

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 6139

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 6139
Study: 23174636

Group type: EXPERIMENTAL
Intervention: LAD occlusion
Number of subjects: 65

Group type: COMPARATOR
Intervention: Diagonal branch occlusion
Number of subjects: 65
Study: 23175735

Group type: EXPERIMENTAL
Intervention: Hospital-based case management (CM)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 280
Study: 23175738

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (five psychoeducational consultations and a 12-week exercise training programme)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 23176444

Group type: EXPERIMENTAL
Intervention: PUSH + PULL
Number of subjects: 670

Group type: COMPARATOR
Intervention: PULL
Number of subjects: 670
Study: 23176611

Group type: EXPERIMENTAL
Intervention: Migalastat hydrochloride, 150 mg orally every-other-day
Number of subjects: 9
Study: 23176709

Group type: EXPERIMENTAL
Intervention: Superficial dry needling (SDN)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 77

Group type: COMPARATOR
Intervention: All participants (SDN and DDN)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Superficial dry needling (SDN) and Deep dry needling (DDN)
Number of subjects: 77
Study: 23178234

Group type: EXPERIMENTAL
Intervention: Behavioral parenting interventions for disruptive behaviors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral parenting interventions for anxiety
Number of subjects: 0
Study: 23178932

Group type: EXPERIMENTAL
Intervention: Standardised mixed meal
Number of subjects: 37
Study: 23178951

Group type: EXPERIMENTAL
Intervention: Amuvatinib dry powder capsules (DPC) 100 to 1,500 mg daily in 28-day cycles
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Amuvatinib dry powder capsules (DPC)
Number of subjects: 22
Study: 23178977

Group type: EXPERIMENTAL
Intervention: Daclatasvir/asunaprevir for 24 weeks
Number of subjects: 43
Study: 23179335

Group type: EXPERIMENTAL
Intervention: Aflibercept 2.0 mg/kg with FOLFIRI
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aflibercept 4.0 mg/kg with FOLFIRI
Number of subjects: 16
Study: 23179562

Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac tromethamine (at delivery)
Number of subjects: 40
Study: 23180114

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily until disease progression or unacceptable toxicity
Number of subjects: 49
Study: 23180239

Group type: EXPERIMENTAL
Intervention: Acute hyperglycemia (PG 231.5 ± 18.1 mg/dl)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Insulin resistance assessed by glucose infusion rate (GIR; mg/kg/min)
Number of subjects: 21
Study: 23180507

Group type: EXPERIMENTAL
Intervention: Intravenous/oral moxifloxacin (MXF, N = 110) 400 mg q.d.
Number of subjects: 206

Group type: COMPARATOR
Intervention: Intravenous piperacillin/tazobactam 4.0/0.5 g t.d.s. followed by oral amoxicillin/clavulanate 875/125 mg b.d. (PIP/TAZ-AMC, N = 96)
Number of subjects: 206
Study: 23182663

Group type: EXPERIMENTAL
Intervention: Sunitinib 50mg p.o. daily for 4 weeks followed by 2 weeks off (6-week cycle)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 24
Study: 23183434

Group type: EXPERIMENTAL
Intervention: PEGIFN/RBV
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PEGIFN AUC >0.79 mg · h/liter
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PEGIFN cumulative 1-week AUC ≤0.79 mg · h/liter
Number of subjects: 42
Study: 23183437

Group type: EXPERIMENTAL
Intervention: GS-9669
Number of subjects: 0
Study: 23183526

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) and asunaprevir (ASV) for 24 weeks
Number of subjects: 43
Study: 23184037

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) in DNI patients
Number of subjects: 780

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV) in patients with no TLD
Number of subjects: 780
Study: 23184668

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 395
Study: 23185357

Group type: EXPERIMENTAL
Intervention: Highest pulse pressure tertile
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Pulse pressure (PP)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Handgrip strength, body weight, age, history of diabetes mellitus
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure, systolic BP, diastolic BP
Number of subjects: 382
Study: 23185385

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 377
Study: 23186837

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with intra-abdominal oesophageal length measurement
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with Collis procedure if intra-abdominal oesophagus <1.5 cm
Number of subjects: 34
Study: 23186915

Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) increase
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: New embolic events in DW-MRI
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Neurological deficit assessed by NIHSS
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Plasma levels of NSE and new emboli in DW-MRI
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Self-sufficiency determined with established score systems (instrumental activities of daily living score, Barthel Index)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: All-cause mortality after 30 days and one year
Number of subjects: 61
Study: 23186936

Group type: EXPERIMENTAL
Intervention: Treatment at discharge for patients with reduced LVEF included ACE inhibitors/ARBs (78%), beta-blockers (67%), and aldosterone inhibitors (27%).
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide testing and echocardiography were performed in over 80% of patients.
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Median hospital stay for patients was 13 days.
Number of subjects: 1658
Study: 23187728

Group type: EXPERIMENTAL
Intervention: Free-breathing radial DCE-MRI
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional VIBE images
Number of subjects: 14
Study: 23187748

Group type: EXPERIMENTAL
Intervention: FDG-PET scans
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 121

Group type: COMPARATOR
Intervention: FDG-PET and CT scans
Number of subjects: 121
Study: 23187897

Group type: EXPERIMENTAL
Intervention: Everolimus plus octreotide LAR
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo plus octreotide LAR
Number of subjects: 44
Study: 23188784

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy with central neck dissection (CND)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Total thyroidectomy without central neck dissection (CND)
Number of subjects: 640
Study: 23189930

Group type: EXPERIMENTAL
Intervention: Normal regular arrangement of collecting venules
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Type A (mosaic-like appearance)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Type B (diffuse homogenous redness)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Type C (untypical pattern)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: All abnormal patterns
Number of subjects: 617
Study: 23190183

Group type: EXPERIMENTAL
Intervention: IFN-γ-1b (100 μg three times per week) added to PEG-IFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 32 weeks after initial 16 weeks of dual therapy.
Number of subjects: 48

Group type: COMPARATOR
Intervention: PEG-IFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 16 weeks (initial dual therapy).
Number of subjects: 48
Study: 23190221

Group type: EXPERIMENTAL
Intervention: Ponatinib (AP24534) administered once daily at doses ranging from 2 to 60 mg.
Number of subjects: 81
Study: 23190385

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 23192220

Group type: EXPERIMENTAL
Intervention: Motivational interviewing + assessment feedback (EARLY)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Informational video
Number of subjects: 217

Group type: COMPARATOR
Intervention: Informational brochure
Number of subjects: 217
Study: 23193189

Group type: EXPERIMENTAL
Intervention: High physiological testosterone gel
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low physiological testosterone gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Castrate levels of testosterone (induced by gonadotropin-releasing hormone agonist treatment)
Number of subjects: 12
Study: 23193207

Group type: EXPERIMENTAL
Intervention: hrA1C
Number of subjects: 3980

Group type: EXPERIMENTAL
Intervention: IFG
Number of subjects: 3980

Group type: COMPARATOR
Intervention: Comparison of hrA1C and IFG
Number of subjects: 3980
Study: 23193944

Group type: EXPERIMENTAL
Intervention: Hereditary TTR amyloidosis
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Wild-type TTR amyloidosis
Number of subjects: 952

Group type: COMPARATOR
Intervention: Asymptomatic carriers of disease-causing mutations
Number of subjects: 952
Study: 23194056

Group type: EXPERIMENTAL
Intervention: Early ASCT
Number of subjects: 167

Group type: COMPARATOR
Intervention: Late ASCT
Number of subjects: 167
Study: 23194193

Group type: EXPERIMENTAL
Intervention: Patients achieving glycaemic goal (HbA(1c) <7%)
Number of subjects: 5817

Group type: EXPERIMENTAL
Intervention: Patients not achieving glycaemic goal (HbA(1c) ≥7%)
Number of subjects: 5817

Group type: EXPERIMENTAL
Intervention: Factors associated with not achieving glycaemic goal
Number of subjects: 5817

Group type: EXPERIMENTAL
Intervention: Bivariate analyses factors associated with not achieving glycaemic goal
Number of subjects: 5817
Study: 23194380

Group type: EXPERIMENTAL
Intervention: Chromium picolinate 500 μg twice a day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Chromium picolinate
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Chromium therapy
Number of subjects: 31
Study: 23194482

Group type: EXPERIMENTAL
Intervention: Prediction rules developed from prospectively gathered evaluation and treatment data in the acute setting (STRATIFY) and early inpatient stay (DECIDE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiology review for assigning post-treatment outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rigorous analysis plan for constructing prediction rules
Number of subjects: 0
Study: 23194494

Group type: EXPERIMENTAL
Intervention: Framingham equation including traditional risk factors
Number of subjects: 19811

Group type: COMPARATOR
Intervention: Framingham equation including traditional risk factors plus CKD and race
Number of subjects: 19811

Group type: COMPARATOR
Intervention: ALLHAT model including CKD and race
Number of subjects: 19811
Study: 23194775

Group type: EXPERIMENTAL
Intervention: In-hospital delirium
Number of subjects: 53

Group type: COMPARATOR
Intervention: No in-hospital delirium
Number of subjects: 53
Study: 23195326

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (1:200,000)
Number of subjects: 0
Study: 23196037

Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 23196955

Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV assay (measuring interferon-γ levels)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV positive result
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV negative result
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV indeterminate result
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Quantiferon-CMV assay
Number of subjects: 127
Study: 23197081

Group type: EXPERIMENTAL
Intervention: Cediranib (45 mg single dose followed by 30 mg continuous once-daily for 21 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cediranib (30 mg continuous once-daily dosing)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 30
Study: 23197234

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 17
Study: 23197288

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitor (PPI) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23197414

Group type: EXPERIMENTAL
Intervention: Vaccine trial with skin biopsy leaving a 6-cm scar
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Vaccine trials requiring skin biopsy leaving a 3-cm scar
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Vaccine trials requiring skin biopsy leaving a 6-cm scar
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Vaccine trials requiring skin biopsy leaving a 12-cm scar
Number of subjects: 91

Group type: COMPARATOR
Intervention: Vaccine trials without biopsy
Number of subjects: 91
Study: 23197589

Group type: EXPERIMENTAL
Intervention: Intraventricular rituximab (10 mg or 25 mg) administered twice weekly for 4 weeks, with rituximab as monotherapy during the first treatment each week and in combination with methotrexate (MTX) during the second treatment each week.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intraventricular rituximab/MTX
Number of subjects: 14
Study: 23199229

Group type: COMPARATOR
Intervention: Prednisolone 75 mg (protocol 2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prednisolone 7.5 mg, 15 mg, 30 mg (protocol 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prednisolone (all doses)
Number of subjects: 42
Study: 23199555

Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: MR-proADM + hs-cTnT
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: MR-proADM + TIMI-score
Number of subjects: 1179
Study: 23199641

Group type: EXPERIMENTAL
Intervention: Physical activity meeting weekly recommendations
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Perceived benefits of exercise
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Perceived barriers to exercise
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Relapse prevention as a benefit of exercise
Number of subjects: 305
Study: 23199894

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC)
Number of subjects: 3643

Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 3643

Group type: EXPERIMENTAL
Intervention: Anti-aggregatory therapy
Number of subjects: 3643

Group type: EXPERIMENTAL
Intervention: Cytoreductive treatment patterns
Number of subjects: 3643
Study: 23200268

Group type: EXPERIMENTAL
Intervention: Low intensity warfarin therapy
Number of subjects: 0